Man Group plc purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 80,496 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,663,000. Man Group plc owned about 0.35% of ANI Pharmaceuticals at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after acquiring an additional 423 shares during the last quarter. Jane Street Group LLC acquired a new stake in ANI Pharmaceuticals during the first quarter worth about $2,706,000. Finally, Norges Bank purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth about $625,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.
Insider Buying and Selling at ANI Pharmaceuticals
In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 5,400 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00. Following the transaction, the chief executive officer owned 344,489 shares of the company’s stock, valued at approximately $25,595,532.70. This trade represents a 1.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the transaction, the senior vice president owned 75,534 shares in the company, valued at $5,816,118. This represents a 4.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 24,387 shares of company stock valued at $1,947,625. 8.10% of the stock is currently owned by insiders.
ANI Pharmaceuticals Stock Performance
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same period in the previous year, the business posted $1.80 EPS. The company’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have weighed in on ANIP shares. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Guggenheim reduced their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.83.
View Our Latest Stock Report on ANIP
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
- Five stocks we like better than ANI Pharmaceuticals
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
